Michael DeRosa

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

Astrocytes: biology and pathology

Tuberous sclerosis complex

Neuronal cytoskeletal abnormalities in human cerebral cortical dysplasia

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

The Tuberous Sclerosis Complex

Glutamate uptake

Neurodevelopmental Disorders as a Cause of Seizures: Neuropathologic, Genetic, and Mechanistic Considerations

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

Delivery technologies for cancer immunotherapy

Children with severe epilepsy: evidence of hippocampal neuron losses and aberrant mossy fiber sprouting during postnatal granule cell migration and differentiation

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

Periventricular Heterotopia: An X-Linked Dominant Epilepsy Locus Causing Aberrant Cerebral Cortical Development

Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions

Plasmapheresis in Rasmussen's encephalitis

Insulin signaling pathways in cortical dysplasia and TSC‐tubers: Tissue microarray analysis

Surgery for Seizures

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

Co‐Localization of TSC1 and TSC2 Gene Products in Tubers of Patients with Tuberous Sclerosis

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Renal cell carcinoma

VEGF in Signaling and Disease: Beyond Discovery and Development

Neuropathologic Study of Resected Cerebral Tissue from Patients with Infantile Spasms

Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice

Systemic Therapy for Metastatic Renal-Cell Carcinoma

Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Alzheimer's disease

Tuberous Sclerosis Complex Consensus Conference: Revised Clinical Diagnostic Criteria

Dentate Granule Cell Neurogenesis Is Increased by Seizures and Contributes to Aberrant Network Reorganization in the Adult Rat Hippocampus

Microscopic cortical dysplasia in infantile spasms: evolution of white matter abnormalities.

The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.

CTLA-4 and PD-1 Pathways

Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review

MR imaging of tuberous sclerosis in neonates and young infants.

Neuropathologic findings in cortical resections (including hemispherectomies) performed for the treatment of intractable childhood epilepsy

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

3011 Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017

Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057

460P Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017

Lung Cancer Symptom Scale (LCSS) as a marker of treatment (tx) benefit with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC from CheckMate 057.